News >

Goy Underscores Impact of BTK Inhibitors in Relapsed/Refractory MCL

Jessica Hergert
Published: Tuesday, Apr 07, 2020

Andre Goy, MD, MS, chief of the Division of Lymphoma, and chairman and director of the John Theurer Cancer Center

Andre Goy, MD, MS

BTK inhibitors have expanded the armamentarium of relapsed/refractory mantle cell lymphoma (MCL), said Andre Goy, MD, MS, adding that this class of agents has elicited unprecedented and durable responses in this patient population.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication